Morrison & Foerster and ChinaBio® are pleased to join together to host a workshop for executives and managers of biotechnology and life science companies interested in learning how to leverage China to raise investment funds, develop new drugs or medical devices, and generate global intellectual property rights. The workshop will include sessions on:
Structuring a Global Life Science Company
Relevant structuring considerations to:
- Enhance financeability by U.S. and China investors
- Maximize tax efficiency
- Provide investor-friendly capital structure
- Preserve flexibility and minimize regulatory approvals for a subsequent liquidity event
Building a Global Patent Portfolio
Secure China, U.S., and international patents to effectively block your competition.
- Significant changes in the U.S. due to the America
Invents Act (AIA)
- Differences between U.S. and China patentability standards
- U.S. court decisions on patentable subject matter
The State of China's Biotech Industry
China’s life science industry is moving quickly from services to innovation. Hear the latest update on novel technology development, investment, M&A and partnering deals, and other news.
Speakers:
- Peng Chen, Partner, Morrison & Foerster LLP
- Steve Rowles, Partner, Morrison & Foerster LLP
- Greg B. Scott, President & Founder, ChinaBio®